Annual EBITDA
$13.54 B
-$10.64 B-44.01%
31 December 2023
Summary:
AbbVie annual earnings before interest, taxes, depreciation & amortization is currently $13.54 billion, with the most recent change of -$10.64 billion (-44.01%) on 31 December 2023. During the last 3 years, it has risen by +$1.21 billion (+9.84%). ABBV annual EBITDA is now -44.01% below its all-time high of $24.17 billion, reached on 31 December 2022.ABBV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
$2.67 B
-$2.33 B-46.53%
30 September 2024
Summary:
AbbVie quarterly earnings before interest, taxes, depreciation & amortization is currently $2.67 billion, with the most recent change of -$2.33 billion (-46.53%) on 30 September 2024. Over the past year, it has dropped by -$2.07 billion (-43.60%). ABBV quarterly EBITDA is now -64.48% below its all-time high of $7.53 billion, reached on 31 March 2022.ABBV Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
$16.02 B
-$2.07 B-11.43%
30 September 2024
Summary:
AbbVie TTM earnings before interest, taxes, depreciation & amortization is currently $16.02 billion, with the most recent change of -$2.07 billion (-11.43%) on 30 September 2024. Over the past year, it has dropped by -$2.99 billion (-15.72%). ABBV TTM EBITDA is now -36.72% below its all-time high of $25.32 billion, reached on 30 September 2022.ABBV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABBV EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -44.0% | -43.6% | -15.7% |
| 3 y3 years | +9.8% | -58.3% | -12.4% |
| 5 y5 years | +62.9% | -10.4% | +145.2% |
ABBV EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -44.0% | +9.8% | -64.5% | at low | -36.7% | at low |
| 5 y | 5 years | -44.0% | +62.9% | -64.5% | +125.4% | -36.7% | +145.2% |
| alltime | all time | -44.0% | +277.6% | -64.5% | +272.5% | -36.7% | +1193.0% |
AbbVie EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $2.67 B(-46.5%) | $16.02 B(-11.4%) |
| June 2024 | - | $5.00 B(+11.5%) | $18.09 B(-2.3%) |
| Mar 2024 | - | $4.49 B(+16.5%) | $18.51 B(+7.8%) |
| Dec 2023 | $13.54 B(-44.0%) | $3.85 B(-18.8%) | $17.17 B(-9.7%) |
| Sept 2023 | - | $4.74 B(-12.5%) | $19.01 B(-11.3%) |
| June 2023 | - | $5.42 B(+71.9%) | $21.43 B(+8.2%) |
| Mar 2023 | - | $3.15 B(-44.5%) | $19.80 B(-18.1%) |
| Dec 2022 | $24.17 B(+1.0%) | $5.69 B(-20.6%) | $24.17 B(-4.5%) |
| Sept 2022 | - | $7.17 B(+89.0%) | $25.32 B(+3.1%) |
| June 2022 | - | $3.79 B(-49.7%) | $24.56 B(-0.8%) |
| Mar 2022 | - | $7.53 B(+10.2%) | $24.75 B(+3.4%) |
| Dec 2021 | $23.93 B(+94.2%) | $6.83 B(+6.5%) | $23.93 B(+30.9%) |
| Sept 2021 | - | $6.41 B(+61.2%) | $18.29 B(+5.7%) |
| June 2021 | - | $3.98 B(-40.8%) | $17.30 B(+16.8%) |
| Mar 2021 | - | $6.71 B(+465.6%) | $14.82 B(+20.2%) |
| Dec 2020 | $12.32 B(+0.8%) | $1.19 B(-78.1%) | $12.32 B(-19.3%) |
| Sept 2020 | - | $5.42 B(+262.9%) | $15.28 B(+19.0%) |
| June 2020 | - | $1.49 B(-64.6%) | $12.84 B(-1.3%) |
| Mar 2020 | - | $4.22 B(+1.9%) | $13.01 B(+6.4%) |
| Dec 2019 | $12.23 B(+47.1%) | $4.14 B(+38.8%) | $12.23 B(+87.1%) |
| Sept 2019 | - | $2.98 B(+79.0%) | $6.53 B(-7.8%) |
| June 2019 | - | $1.67 B(-51.5%) | $7.08 B(-13.5%) |
| Mar 2019 | - | $3.43 B(-321.4%) | $8.19 B(-1.4%) |
| Dec 2018 | $8.31 B(-19.9%) | -$1.55 B(-143.9%) | $8.31 B(-29.1%) |
| Sept 2018 | - | $3.54 B(+27.4%) | $11.72 B(+7.0%) |
| June 2018 | - | $2.77 B(-21.9%) | $10.95 B(-2.2%) |
| Mar 2018 | - | $3.55 B(+90.8%) | $11.20 B(+7.9%) |
| Dec 2017 | $10.38 B | $1.86 B(-32.7%) | $10.38 B(-7.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2017 | - | $2.77 B(-8.3%) | $11.16 B(+1.6%) |
| June 2017 | - | $3.02 B(+10.4%) | $10.98 B(+3.6%) |
| Mar 2017 | - | $2.73 B(+3.4%) | $10.59 B(+4.7%) |
| Dec 2016 | $10.12 B(+23.4%) | $2.64 B(+2.0%) | $10.12 B(+2.5%) |
| Sept 2016 | - | $2.59 B(-1.6%) | $9.87 B(+5.4%) |
| June 2016 | - | $2.63 B(+16.4%) | $9.36 B(+6.7%) |
| Mar 2016 | - | $2.26 B(-5.6%) | $8.77 B(+7.0%) |
| Dec 2015 | $8.20 B(+128.8%) | $2.39 B(+15.0%) | $8.20 B(+60.7%) |
| Sept 2015 | - | $2.08 B(+2.0%) | $5.10 B(+26.0%) |
| June 2015 | - | $2.04 B(+21.0%) | $4.05 B(+8.9%) |
| Mar 2015 | - | $1.69 B(-339.1%) | $3.72 B(+3.7%) |
| Dec 2014 | $3.58 B(-45.1%) | -$705.00 M(-168.6%) | $3.58 B(-40.3%) |
| Sept 2014 | - | $1.03 B(-39.9%) | $6.00 B(-8.6%) |
| June 2014 | - | $1.71 B(+9.8%) | $6.57 B(+0.4%) |
| Mar 2014 | - | $1.55 B(-9.2%) | $6.55 B(+0.3%) |
| Dec 2013 | $6.53 B(-6.5%) | $1.71 B(+7.4%) | $6.53 B(-5.8%) |
| Sept 2013 | - | $1.59 B(-5.2%) | $6.93 B(-3.4%) |
| June 2013 | - | $1.68 B(+9.4%) | $7.18 B(-0.2%) |
| Mar 2013 | - | $1.54 B(-27.3%) | $7.19 B(+3.1%) |
| Dec 2012 | $6.98 B(+41.3%) | $2.12 B(+14.9%) | $6.98 B(+10.1%) |
| Sept 2012 | - | $1.84 B(+8.5%) | $6.34 B(+30.2%) |
| June 2012 | - | $1.70 B(+28.1%) | $4.87 B(-3.1%) |
| Mar 2012 | - | $1.32 B(-10.4%) | $5.03 B(+1.7%) |
| Dec 2011 | $4.94 B(-17.9%) | $1.48 B(+300.8%) | $4.94 B(+42.7%) |
| Sept 2011 | - | $368.85 M(-80.1%) | $3.46 B(+11.9%) |
| June 2011 | - | $1.85 B(+49.6%) | $3.09 B(+149.6%) |
| Mar 2011 | - | $1.24 B | $1.24 B |
| Dec 2010 | $6.02 B(+3.8%) | - | - |
| Dec 2009 | $5.80 B | - | - |
FAQ
- What is AbbVie annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for AbbVie?
- What is AbbVie annual EBITDA year-on-year change?
- What is AbbVie quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for AbbVie?
- What is AbbVie quarterly EBITDA year-on-year change?
- What is AbbVie TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for AbbVie?
- What is AbbVie TTM EBITDA year-on-year change?
What is AbbVie annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ABBV is $13.54 B
What is the all time high annual EBITDA for AbbVie?
AbbVie all-time high annual earnings before interest, taxes, depreciation & amortization is $24.17 B
What is AbbVie annual EBITDA year-on-year change?
Over the past year, ABBV annual earnings before interest, taxes, depreciation & amortization has changed by -$10.64 B (-44.01%)
What is AbbVie quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ABBV is $2.67 B
What is the all time high quarterly EBITDA for AbbVie?
AbbVie all-time high quarterly earnings before interest, taxes, depreciation & amortization is $7.53 B
What is AbbVie quarterly EBITDA year-on-year change?
Over the past year, ABBV quarterly earnings before interest, taxes, depreciation & amortization has changed by -$2.07 B (-43.60%)
What is AbbVie TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ABBV is $16.02 B
What is the all time high TTM EBITDA for AbbVie?
AbbVie all-time high TTM earnings before interest, taxes, depreciation & amortization is $25.32 B
What is AbbVie TTM EBITDA year-on-year change?
Over the past year, ABBV TTM earnings before interest, taxes, depreciation & amortization has changed by -$2.99 B (-15.72%)